Recurrence risk prediction is an essential step towards personalization of cancer treatment. Up to 3 out of 4 early-stage, hormone receptor-positive breast cancer patients may not benefit from chemotherapy. This makes accurate risk prediction an all-important prerequisite for effective treatment. It is, therefore, necessary to detect low-risk instances to avoid overtreatment in the form of chemotherapy, given its side effects and the toll it takes on the patients’ quality of life.

If you have been recently diagnosed with early-stage invasive breast cancer, there is a possibility that you may not require chemotherapy. CanAssist Breast test provides additional information about the tumor. Along with the existing pathology report, this test result lets you know the likelihood of cancer returning at a distant site after surgery and whether you are likely to benefit from chemotherapy or not.

Knowing the patient's recurrence risk allows the doctors to devise treatment plans that are in-tune with the prognosis, thereby, maintaining an optimal balance between the benefits and side-effects. It makes customized treatment possible while keeping the costs down in low-risk cases.

You can get to know your risk of recurrence using the CanAssist Breast test. CanAssist Breast uses a proteomics- based method to analyze a patented combination of protein biomarkers from the patient’s tumor to compute the risk of recurrence of cancer using our proprietary machine learning based algorithm. Our test integrates IHC (immunohistochemistry) data and clinical parameters into a statistical algorithm that provides a risk score that classifies patients as ‘low-risk’ or ‘high-risk’ for breast cancer recurrence over five years. The CanAssist Breast test result allows breast cancer patients who are classified as ‘low-risk’ to avoid potentially chemotherapy and its side effects.